In Westlaw Practical Law Q&A, Joshua Oyster Analyzes Federal Regulation of Psychedelic Therapies

In The News
July 16, 2024
Attorneys:

In a Westlaw Practical Law Q&A column, life sciences regulatory & compliance partner Joshua Oyster reviewed the federal legal and regulatory framework that controls the research, approval and marketing of psychedelic drug products.

The Q&A addresses topics such as the types of drugs that are categorized under the term “psychedelic”, the role of the Food and Drug Administration and the Drug Enforcement Administration in authorizing and controlling the use of psychedelics for therapeutic medical purposes, including during the research phase of drug development, recent litigation, and potential legislation to make psychedelics more accessible to the medical community.